Literature DB >> 26081814

FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma.

Jun Xin1, Xue-Kui Zhang1, De-You Xin2, Xian-Feng Li1, De-Ke Sun1, Yue-Ye Ma1, Li-Qiang Tian3.   

Abstract

Glioblastoma is the most common primary malignancy of the adult central nervous system (CNS) and is associated with an exceptionally poor prognosis. Elucidation of the pathogenesis and molecular changes will help us to further understand the pathogenesis and progression of the disease and offer new therapeutic targets. FUS1 (TUSC2, tumor suppressor candidate 2) is a tumor-suppressor gene located on human chromosome 3p21. Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells. Yet, its role in human glioblastoma has rarely been addressed. In the present study, we demonstrated that low expression of FUS1 was detected in high-grade human glioma, implying that FUS1 expression is negatively associated with progression of the disease. Subsequent studies confirmed that FUS1 overexpression inhibited the proliferation, migration and invasion of human glioblastoma cells. In addition, we found that FUS1 overexpression significantly upregulated miR-197 expression in the glioblastoma cells. We also revealed that miR-197 suppressed the proliferation, migration and invasion of the cells as well as the silencing of miR-197 attenuated the biological functions of FUS1. Using human glioblastoma tissue samples, we demonstrated that miR-197 is negatively associated with metastasis. All the results demonstrated that FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma and implied that restoration of FUS1 and miR-197 could be new therapeutic strategies for glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26081814     DOI: 10.3892/or.2015.4069

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.

Authors:  Tadas Rimkus; Sherona Sirkisoon; Alexandra Harrison; Hui-Wen Lo
Journal:  Discov Med       Date:  2017-05       Impact factor: 2.970

2.  NEDD4 degrades TUSC2 to promote glioblastoma progression.

Authors:  Tadas K Rimkus; Austin B Arrigo; Dongqin Zhu; Richard L Carpenter; Sherona Sirkisoon; Daniel Doheny; Angelina T Regua; Grace L Wong; Sara Manore; Calvin Wagner; Hui-Kuan Lin; Guangxu Jin; Jimmy Ruiz; Michael Chan; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2022-02-12       Impact factor: 8.679

3.  Machine learning and bioinformatics approaches for classification and clinical detection of bevacizumab responsive glioblastoma subtypes based on miRNA expression.

Authors:  Jian Shi
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

4.  MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling.

Authors:  Melina M Musri; Núria Coll-Bonfill; Bradley A Maron; Víctor I Peinado; Rui-Sheng Wang; Jordi Altirriba; Isabel Blanco; William M Oldham; Olga Tura-Ceide; Jessica García-Lucio; Benjamin de la Cruz-Thea; Gunter Meister; Joseph Loscalzo; Joan A Barberà
Journal:  Am J Respir Cell Mol Biol       Date:  2018-10       Impact factor: 6.914

5.  miR-663b promotes tumor cell proliferation, migration and invasion in nasopharyngeal carcinoma through targeting TUSC2.

Authors:  Shaoqiang Liang; Ning Zhang; Yanming Deng; Lusi Chen; Yang Zhang; Zhenhe Zheng; Weijun Luo; Zhiqian Lv; Shaoen Li; Tao Xu
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

6.  Oncogenic Role of MicroRNA-30b-5p in Glioblastoma Through Targeting Proline-Rich Transmembrane Protein 2.

Authors:  Zhongjun Li; Junxiu Guo; Yujie Ma; Longbo Zhang; Zhixiong Lin
Journal:  Oncol Res       Date:  2017-05-17       Impact factor: 5.574

Review 7.  Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications.

Authors:  Roman Uzhachenko; Akiko Shimamoto; Sanika S Chirwa; Sergey V Ivanov; Alla V Ivanova; Anil Shanker
Journal:  Cancer Gene Ther       Date:  2022-02-18       Impact factor: 5.854

8.  L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer.

Authors:  Jinlong Chen; Fufeng Gao; Naifu Liu
Journal:  Exp Ther Med       Date:  2018-01-12       Impact factor: 2.447

9.  The TUSC2 Tumour Suppressor Inhibits the Malignant Phenotype of Human Thyroid Cancer Cells via SMAC/DIABLO Protein.

Authors:  Raffaela Mariarosaria Mariniello; Francesca Maria Orlandella; Anna Elisa De Stefano; Paola Lucia Chiara Iervolino; Giovanni Smaldone; Neila Luciano; Nara Cervone; Francesco Munciguerra; Silvia Esposito; Peppino Mirabelli; Giuliana Salvatore
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.